#diabetes management #Switzerland #Basel #Accu-Chek #mySugr

Roche Enhances Diabetes Care with Accu-Chek SmartGuide and mySugr Integration

Roche has made a significant advancement in diabetes management with the recent announcement of its Accu-Chek SmartGuide continuous glucose monitoring (CGM) system, paired with the popular mySugr diabetes management app. This integration received the CE Mark approval, enhancing the way individuals manage diabetes by providing a seamless and comprehensive solution that simplifies the complexities of daily diabetes care.

What is Accu-Chek SmartGuide?

The Accu-Chek SmartGuide is not just another glucose monitor; it's a sophisticated CGM system that utilizes artificial intelligence to predict glucose levels, offering users predictive insights that can aid in preventing hypoglycemia and hyperglycemia. This tool is designed for individuals aged 18 and older with type 1 or type 2 diabetes. With features that allow readings of glucose levels in real-time and the ability to forecast these levels up to two hours ahead, it's a vital tool for proactive diabetes management.

As part of Roche's ongoing commitment to improving the lives of those affected by diabetes, the SmartGuide is accessible in 13 countries as of now, with plans for expansion to over 30 additional countries by the end of 2025.

Integration with mySugr App

The mySugr app, which has been widely adopted since its launch in 2012, integrates seamlessly with the Accu-Chek SmartGuide. This user-friendly application allows users to log their meals, track insulin usage, and analyze their glucose patterns all in one place. Users can make informed decisions regarding their diabetes management, enhancing not just their health but also their confidence in handling their condition.

Key functions of the mySugr app include:

• - Logging and analyzing glucose values right alongside dietary intake.
• - Utilizing the mySugr Bolus Calculator to help with accurate insulin dosing and management.
• - Connecting with other compatible devices for comprehensive glucose insights.

Studies have shown that mySugr’s logging tool has significantly reduced severe hypo- and hyperglycemic episodes, affirming its effectiveness in managing diabetes stress over time.

Clinical Relevance and Real-world Evidence

At the European Association for the Study of Diabetes (EASD) Annual Meeting, Roche presented compelling real-world evidence underscoring the effectiveness of the SmartGuide system. Clinical evaluations displayed a mean absolute relative difference (MARD) of 9.2%, confirming the system's accuracy and reliability. Additionally, the predictive capabilities of the CGM exceeded performance expectations, illustrating a vital step towards making diabetes care more personalized and manageable.

Dr. Jackie Elliott, Clinical Lead for Diabetes, emphasized the importance of such predictive tools, stating, “Living with diabetes requires balancing numerous factors. Solutions that provide actionable insights and context-aware alerts are crucial for empowering patients to navigate their diabetes with less anxiety.”

The results also reveal that the Night Low Predict feature can reduce the likelihood of hypoglycemic events during the night significantly, showcasing its protective benefits without increasing risks of hyperglycemia—a critical balance for those reliant on insulin.

Moving Forward

Roche’s integration of the Accu-Chek SmartGuide with mySugr strengthens their commitment to providing a holistic approach to diabetes care. As CGM technology becomes the standard for diabetes management, innovations like this are not only necessary but are crucial in supporting individuals in achieving better health outcomes. With over 6 million users, mySugr’s ability to consolidate therapy data, combined with the advanced predictive analytics of the Accu-Chek SmartGuide, represents a hopeful future for diabetes management.

With ongoing efforts to roll out these innovations across more regions, Roche is paving the way for enhanced care, ensuring that everyone living with diabetes has the tools they need to manage their condition effectively and confidently.

In conclusion, Roche's latest development is not merely a technological advancement; it’s a beacon of hope for millions affected by diabetes, emphasizing that with the right tools, improved health outcomes and everyday management are well within reach.